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AnAlysIs of Cost MInIMIzAtIon of AdAlIMuMAb CoMPAred WIth 
InflIxIMAb for the treAtMent of ulCerAtIve ColItIs In the PublIC 
MArket In MexICo
Pichardo-Piña CA, Sanchez-Casillas JL
AbbVie, Distrito Federal México, Mexico
Objectives: Determine whether adalimumab reduces costs for the public health 
sector in the treatment of moderate to severe active ulcerative colitis in adult 
patients who have had an inadequate response to conventional therapy in com-
parison with infliximab. MethOds: Adalimumab was considered comparable 
with infliximab in the treatment of Ulcerative Colitis through a systematic review 
of the literature. A cost minimization analysis was then considered appropriate 
under the perspective of the public health care system in Mexico and a time 
horizon of five years. Direct drug and administration costs were considered. 
Univariate and multivariate probabilistic sensitivity analyses were performed. 
Finally, we assessed the budget impact of potential savings. Results: The model 
Resultsshowed that the cost with adalimumab treatment for five years (using an 
annual discount rate of 5%) is $ 96,365.87 (11.2%) lower than the total cost with 
infliximab. This generates savings to the health system. Resultshave a high sensi-
tivity to patient weight, but expected costs in all simulated populations are lower 
with adalimumab. In the base case, the present value of the 5-year budget impact 
with a discount rate of 5% represents savings around $ 348,748,074.14 pesos if 
adalimumab is used in 100% of estimated prevalence in Mexico. cOnclusiOns: 
Adalimumab proved to be an alternative that minimizes expected costs under 
the investigated scenarios given the evidence of comparable efficacy versus inf-
liximab. Also, savings allow greater access to care for patients with UC, benefiting 
the health institution, not only by improving the quality of care with an innova-
tive therapy but also by allowing significant savings that could be used to treat a 
larger number of patients.
GAstroIntestInAl dIsorders – Patient-reported outcomes & Patient  
Preference studies
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AssessMent of CoMPleMentAry And AlternAtIve MedICIne use In 
hePAtItIs-C PAtIents In QuettA, PAkIstAn
ul Haq N, Shah A, Iqbal Q, Naseem A, Akram A, Mohammd S
University of Balochistan, Quetta, Pakistan
Objectives: The Study Was Conducted to evaluate the use of complementary 
and alternative medicine in Hepatitis-C patients In Quetta, Pakistan MethOds: 
A cross sectional study was conducted from March to September, 2014. Hepatitis-C 
patients having confirm diagnosis visiting different facilities in Quetta city for 
the treatment of their disease, were included in the study. The data was collected 
by use of pre-validated tool made specifically for this study. The descriptive sta-
tistics was used to present the demographic and disease related information. All 
analyses were performed using SPSS 20.0. Results: A total of 389 patients were 
registered in different health facilities of the study out of which 284 patients 
agree to participate in the study. One hundred and seventy two (60.5 %) were 
using complementary and alternative medicine for the treatment of their disease 
along with conventional therapy, Herbal treatment was majorly practiced (41.9 
%) complementary and alternative method, followed by religious Methods(35.0 
%). One hundred and thirty two (76.7 %) of these consult a complementary and 
alternative medicine practitioner. Majority (N= 154, 90%) of the respondents were 
satisfied with the Complementary and Alternative Medicine Methodsthey used 
for treatment of Hepatitis C. cOnclusiOns: The findings of the study show that 
the use of Complementary & Alternative Medicine is prevalent in Hepatitis-C 
patients in Quetta, Pakistan. People satisfied with the use of Complementary 
& Alternative Medicine methods. Further research is needed to evaluate the 
reasons and outcomes for Complementary & Alternative Medicine use by 
patients.
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A hePAtIte C CrônICA dIMInuI A QuAlIdAde de vIdA?
Perlin CM, Borba HH, Wzorek LF, Piazza T, Madeira C, Pontarolo R, Wiens A
Universidade Federal do Paraná, Curitiba, Brazil
ObjetivOs: Verificar se há diferença na qualidade de vida entre pacientes por-
tadores da hepatite C que estão em tratamento (com interferon peguilado mais 
ribavirina associado ou não a um inibidor de protease) com aqueles que não estão 
em tratamento. MétOdOs: Estudo observacional, transversal mediante a apli-
cação de 3 questionários auto-administráveis sendo dois genéricos: Short Form 36 
Questionnaire (SF-36) e Euroqol 5D (EQ-5D) e um específico para doenças hepáti-
cas: Chronic Liver Disease Questionnaire (CLDQ). Os questionários foram aplicados 
em pacientes com hepatite C após a aprovação pelo Comitê de Ética do Hospital de 
Clínicas da Universidade Federal do Paraná e da Secretaria Municipal de Saúde de 
Curitiba, Paraná. Os pacientes assinaram o termo de consentimento livre esclare-
cido (TCLE). Os dados coletados foram tabelados no programa Microsoft Excel 2013 
e a análise estatística feita pelo programa Minitab® 17. ResultAdOs: Através da 
prova de Mann-Whitney (IC 95%), obteve-se diferença estatisticamente signifi-
cante (p< 0,05) no SF-36 nos domínios aspectos físicos e aspectos emocionais assim 
como no CLDQ nos domínios: fadiga, sintomas sistêmicos, atividades, função 
emocional. Não houve tal diferença (p< 0,05) no EQ-5D, porém o valor utility médio 
para pacientes em tratamento foi de 0,661 e para os não tratados 0,733 assim 
como o valor médio da escala analógica visual (VAS) sendo respectivamente 0,57 
e 0,73. cOnclusões: A administração de questionários genéricos com o suporte 
de um questionário específico, que é sensível a aspectos peculiares da doença, 
evidencia que o tratamento tem uma influência negativa na qualidade de vida dos 
pacientes com hepatite C denotando um maior cuidado no manejo dos mesmos 
pela equipe de saúde.
Objectives: To estimate the direct costs of HCV management for genotype 1 
patients throughout their lifetime based on the natural history of the disease from 
payer perspective in Colombia MethOds: Direct costs were estimated from a 
payer perspective by using a micro-costing approach of all relevant resources used 
to manage patients with HCV genotype 1 since the diagnosis for a lifetime perspec-
tive. Resources and clinical practice were identified, measured and valued for nine 
health states. Resource use and clinical patterns were validated with a panel of 
experts in managing HCV patients by applying a comprehensive survey. Each of the 
resources was valued based on standard national public lists of fees in Colombian 
pesos. Total costs for each of the health states of the disease were calculated for 
a one year time horizon Results: Direct cost were presented in US Dollars using 
the average year to date exchange rate (USD 1 = COP 1,974). Estimated average 
direct cost for each health state per year non diagnostic HCV (USD 512), chronic 
HCV F0-F3 (USD 1,440), compensated cirrhosis (USD 976), decompensated cirrhosis 
(USD 10,782), hepatocellular carcinoma (USD 10,263), liver transplantation (USD 
28,883), post-transplant (USD 1,933), monitoring drug therapy for HCV and the 
management of adverse events (USD 1,020), death (USD 15,538). cOnclusiOns: 
Chronic HCV infection represents an important economic and humanistic bur-
den for health systems in the world. This micro-costing study provides valuable 
information for further economic cost of illness analysis from the Colombian 
payers setting. It also reflects severity and economic impact of HCV related health 
states.
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Objectives: To estimate the impact on costs resulting from expanded biologics 
use in treating Crohn’s disease (CD) in Latin America over 10 years. MethOds: The 
influence of increasing biologics use for CD therapy during 2013–2023 was mod-
eled from a societal perspective. The model incorporated current and projected 
changes in medical (inpatient and outpatient services), indirect (productivity loss), 
and drug costs; population size; gross domestic product; and CD prevalence. Costs 
associated with expanded biologics use (estimated annual rate of increase 7.41%, 
21.07%, and 4.97% in Brazil, Colombia, and Mexico, respectively) were compared 
with non-expanded use (no increase from 2013 levels). The expanded-use sce-
nario incorporated additional drug costs and benefits (medical and indirect cost 
reduction) attributed to expanded biologics use. Average annual per-patient costs 
of CD therapy and cost offsets based on biologics use were aggregated with base 
annual medical and indirect costs to estimate total cost per patient. Total per-
country annual costs were estimated using population size and CD prevalence. 
Costs were adjusted to currency year 2013. Sensitivity analyses of model inputs 
(CD prevalence and growth of prevalence) assessed model robustness. Results: 
Expanded biologics use was associated with slower annual cost growth vs. non-
expanded use; projected per-patient 2023 costs were R$19,689 vs. R$22,235 in 
Brazil, COP$15.70 million vs. COP$18.66 million in Colombia, and MXN$76,353 
vs. MXN$82,170 in Mexico. Differences were driven by greater medical and indi-
rect cost offsets with expanded vs. non-expanded use (e.g., R$4,390 vs. R$2,148 
[medical] and R$6,723 vs. R$3,290 [indirect]). Expanded biologics use resulted in 
10-year cumulative net cost savings of R$0.08 billion in Brazil, COP$503 billion in 
Colombia, and MXN$1.8 billion in Mexico. cOnclusiOns: Increasing biologics 
use to treat CD may limit cost growth over time by reducing medical and indirect 
costs. These findings may inform policy decisions regarding biologics use for CD 
in Latin America.
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Custo-efetIvIdAde do tenofovIr PArA o trAtAMento dA hePAtIte b 
CrônICA uMA revIsão sIsteMátICA
Balbinot JC1, Wiens A2, Pontarolo R2, Sanches AC1
1Universidade Estadual do Oeste do Paraná, Cascavel, Brazil, 2Universidade Federal do Paraná, 
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ObjetivOs: O objetivo desse estudo foi realizar uma revisão sistemática sobre 
custo-efetividade do tenofovir para o tratamento de pacientes com hepatite B 
crônica. MétOdOs: Foi realizada uma extensiva busca sistemática na literatura 
por meio das bases de dados Pubmed, Scopus, ScienceDirect, Cochrane, Scielo, HTA 
e ISPOR, além da busca manual, de artigos publicados até fevereiro de 2015. As 
estratégias utilizadas foram “cost-effectiveness” OR “cost-utility” AND “hepatitis 
B treatment” AND “tenofovir”. Os estudos incluídos foram referentes a avaliações 
econômicas do tipo custo-efetividade e custo-utilidade em pacientes adultos e 
portadores de Hepatite B crônica. A intervenção utilizada foi o uso de tenofovir 
em comparação às outras alternativas para o tratamento da doença (lamivudina, 
telbivudina, adefovir, entecavir, interferon alfa e interferon alfa peguilado) e/ou 
nenhum tratamento. Os desfechos avaliados foram os custos relacionados com 
as melhorias de saúde (RCEI, AVAQ e AVG). ResultAdOs: Ao total, 1185 artigos 
foram encontrados e apenas 15 atendiam aos critérios de inclusão. O tenofovir foi a 
estratégia mais custo-efetiva em 2/3 dos artigos selecionados. Nos demais estudos, 
o fator limitante para o tenofovir ser classificado como a melhor estratégia, foi 
o seu custo, pois é possível observar que houveram melhorias nos desfechos em 
saúde avaliados, sendo em alguns casos tão efetivo quanto as alternativas domi-
nantes. cOnclusões: Resultados relevantes foram encontrados, sugerindo que 
o tenefovir é o medicamento mais custo-efetivo para o tratamento da hepatite B 
crônica e também como terapia de resgate. O seu baixo risco de desenvolvimento 
de resistência, aliado ao efeito de proporcionar melhorias na saúde em anos de 
vida ganhos e anos de vida ajustados pela qualidade, além de diminuir as taxas 
de incidência de cirrose, hepatocarcinoma celular e transplantes hepáticos refor-
çam esse resultado. Os desfechos demonstrados podem contribuir na tomada de 
decisão do clínico, na busca pela melhor alternativa para o paciente.
